a building that has a lot of trees in front of itPhoto by Thomas Gabernig
  • New data from Novartis shows promising results for Leqvio® in cholesterol management
  • Leqvio® effectively lowers LDL-C levels when combined with statin therapy
  • Significant improvements observed in patients with atherosclerotic cardiovascular disease

Basel, Switzerland — Novartis data showed Sunday that Leqvio reduces LDL-C in ASCVD patients when added early after statin therapy.

This latest study, focused on patients with atherosclerotic cardiovascular disease (ASCVD), reveals significant reductions in low-density lipoprotein cholesterol (LDL-C), offering hope for those not achieving desired results with statin therapy alone.

Presented at the prestigious 2024 American College of Cardiology’s Annual Scientific Session & Expo and published simultaneously in the Journal of the American College of Cardiology, the study emphasizes the importance of early intervention. Leqvio®, administered biannually, demonstrated a marked improvement in cholesterol management among ASCVD patients, including those with a history of ASCVD-related events. This underscores the drug’s potential as a critical component in cardiovascular disease management strategies.

According to the study, patients who added Leqvio® to their existing statin therapy observed a significant reduction in LDL-C levels. This is particularly noteworthy for patients who previously struggled to reach their cholesterol goals through statin therapy alone, highlighting Leqvio®’s role in filling a vital treatment gap.

The results are seen as a significant advancement in the fight against cardiovascular disease, the leading cause of death globally. By effectively lowering LDL-C levels, a key risk factor for heart attacks and strokes, Leqvio® offers a new hope for patients at risk.

In summary, the integration of Leqvio® into treatment regimens could revolutionize the approach to managing cholesterol levels, particularly in ASCVD patients. This development marks a significant stride in Novartis’ commitment to addressing unmet medical needs in cardiovascular health.

By Lisa Luckas

Lisa Luckas is a Sr. Business News Editor at Nobot.News.

Leave a Reply

Your email address will not be published. Required fields are marked *

GDPR Cookie Consent with Real Cookie Banner